

## Change in number of shares and votes in SynAct Pharma AB

**SynAct Pharma AB (the "Company") announces that the number of shares and votes has increased by 856,625 as a result of the directed share issue, which was executed in June 2025.**

Today, the last trading day of the month, the total number of shares and votes in the Company amounts to 49,874,543. The total number of shares in the share issue was 2,313,125, where the remaining part of 1,456,500 shares is planned for registration at the Swedish Company Office in July 2025.

For further information, please contact:

Björn Westberg, CFO SynAct Pharma

Tel: +46 733 940 953

Email: [investor.relations@synactpharma.com](mailto:investor.relations@synactpharma.com)

About SynAct Pharma AB

SynAct Pharma AB (publ) (Nasdaq Stockholm: SYNACT) is a clinical stage biotechnology company focused on resolving inflammation through selective activation of the melanocortin system. The company has a broad portfolio of oral and injectable selective melanocortin agonists aimed at inducing anti-inflammatory and anti-inflammatory activity in autoimmune and inflammatory diseases to help patients achieve immune balance and overcome their inflammation. For more information: [www.synactpharma.com](http://www.synactpharma.com).

### Attachments

*This information is information that SynAct Pharma is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 2025-06-30 18:00 CEST.*

### Attachments

[Change in number of shares and votes in SynAct Pharma AB](#)